The IPO Buzz: Rezera (RZRA Proposed) Unveils Terms for $200 Million IPO
Rezera Inc. (RZRA Proposed), a Boston biotech planning a Phase 3 trial in 2027 of its leading drug candidate to treat peripheral artery disease (PAD), unveiled the terms for its $200 million IPO early today – Thursday, Nov. 5, 2026 - in an S-1/A filing. Rezera is offering 16.67 million shares at a price range of $11.00 to $13.00 to raise $200 million, if priced at the $12.00 mid-point of its ra..
Read more November 5, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| Primagrove | YNTE | 6.3 | $ 30.5 mil | 11/9/2026 Week of | S/O | S/O |
| Rezera Inc. | RZRA | 16.7 | $ 200.0 mil | 11/12/2026 Thursday | S/O | S/O |
| Bitari | BIAI | 4.3 | $ 30.0 mil | 11/16/2026 Week of | S/O | S/O |
Last 100 IPOs - November 4, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 42 |
| Number Down: | 56 |
| Number Unchanged: | 2 |
| Percentage Change From Issue Price: | 0.07% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - November 4, 2026
| Number of IPOs priced (Excluding 154 units) : | 138 |
| Number Up: | 53 |
| Number Down: | 83 |
| Number Unchanged: | 2 |
| Total Return From Issue Price: | -1.49% |
| The Nasdaq Composite Index YTD % Change | 35.22% |